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Although it is common to see pharmacogenomic testing used North America and Australia, it is not 
yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, 
pharmacists must equip themselves with a knowledge of how the process works. 
 
Source: Shutterstock.com 
In January 2019, the UK government unveiled its ten-year plan for NHS England and emphasised the 
role pharmacists can play in promoting patient self-care[1]. There was also a focus on delivering value 
from medicines and reducing avoidable medicines related-harm, which costs the NHS a minimum of 
£98.5m per year[2]. This coincides with the NHS Genomic Medicine Service, which will be rolled out 
across England from April 2020, meaning that the routine use of genomic screening and personalised 
treatments will be the new normal in the NHS[3],[4].  
Pharmacists’ advice currently relies on knowledge of observable patient characteristics, such as age, 
weight, comorbidities and concurrent medicines, while largely disregarding genetics. However, it is 
estimated that genetic factors could contribute to between 25–50% of inappropriate drug responses[5]. 
Knowing exactly which medicine to use for a patient and which to avoid can be a challenging task in 
clinical practice. However, pharmacogenomics can provide the prescriber with additional information 
on some of the unobserved patient characteristics that affect drug response — this can assist with 
both drug selection and safety. Therefore, the combination of this pharmacogenomic information 
along with other factors influencing pharmaceutical care may provide an opportunity to deliver more 
‘personalised’ medicine, facilitating better selection and reducing the need for ‘trial and error’ 
prescribing. 
Pharmacogenomics is an emerging field that studies how genes affect a person’s response to 
medicines[6]. It looks at how an individual’s genes influence a particular biological process that 
mediates the effects of a medicine[7]. 
One of the main barriers to the implementation of pharmacogenomics in clinical practice has been the 
translation of pharmacogenomic knowledge to that which is actionable and usable in the clinic[8]. 
Fortunately, progress has been made in this area and several organisations now develop guidance to 
support prescribing where a drug–gene association is established. Examples include: 
• The Clinical Pharmacogenetics Implementation Consortium; 
• The Dutch Pharmacogenetics Working Group; 
• The Canada Pharmacogenomics Network for Drug Safety. 
The most extensively studied genetic polymorphisms in pharmacogenes (genes involved in 
pharmaceutically relevant biological pathways affecting the response of one or several drugs) that are 
now being used in practice can be seen in Table 1. These variations are found in in the genes 
encoding: 
1. Cytochrome P450 drug metabolising enzymes; 
2. Drug transporters; 
3. The human leukocyte antigen B proteins[9]. 
The extent to which an individual pharmacogene influences overall drug response is dependent on 
the gene in question, in addition to other factors known to influence the drug’s pharmacokinetic and/or 
pharmacodynamic properties. For example, if the gene in question controls the production of a 
particular drug-metabolising enzyme, then the significance of this will depend on:  
• Whether the drug is metabolised primarily by the enzyme in question; 
• The relationship between plasma concentration and efficacy/toxicity; 
• Whether the drug is an active drug or a prodrug; 
• Whether there are any inhibitors or inducers of the drug-metabolising 
enzyme present, which can further alter the phenotype of the enzyme by a 
process known as phenoconversion[10]. 
Table 1: Examples of important pharmacogenes 
Important 
pharmacogenes 
Examples of clinical impact 
Cytochrome P450 genes 
e.g. CYP2D6, CYP2C19, 
CYP2C9 
The CYP2D6 enzyme metabolises around 25% of drugs in clinical 
use, including many psychotropics, opioid analgesics and other 
classes of medicines. Poor metabolisers of the CYP2D6 enzyme 
have been found to be at increased risk of side effects when taking 
medicines like venlafaxine, aripiprazole and amitriptyline. The 
CYP2C19 metaboliser state has implications for the antiplatelet drug 
clopidogrel, many of the proton pump inhibitors and many 
antidepressants. CYP2C9 is important for calculating the starting 
daily dose for warfarin and is useful for predicting the risk of side 
effects for several non-steroidal anti-inflammatory drugs. 
Drug transporter 
genes  e.g. SLCO1B1 
Drug transporters mediate the active transport of both endogenous 
substrates and xenobiotic compounds. One of the most extensively 
Table 1: Examples of important pharmacogenes 
Important 
pharmacogenes 
Examples of clinical impact 
studied genes is SLCO1B1, which encodes the OATP1B1 drug 
transporter responsible for statin uptake into the liver. People who 
carry a particular genetic variant in the SLC01B1 gene produce a 
transporter with reduced function. This increases the circulating 
plasma concentration of statins which is associated with an 
increased risk of myopathy. The association is strongest with 
simvastatin, for which pharmacogenomic guidelines exist 
recommending drug/dose changes. 
Human leukocyte 
antigen-B (HLA-B) genes 
e.g. HLA-B*1502 
The human leucocyte antigen-B gene codes for cell-surface 
molecules that are responsible for presenting endogenous peptides 
to circulating T-cells. Variants of this gene have been associated 
with Type B adverse drug reactions in a wide number of drugs 
including abacivir, flucloxacillin, allopurinol, carbamazepine and 
phenytoin. For example, the presence of the HLA-B*1502 allele in 
those of a Han Chinese, Hong Kong Chinese or Thai origin is 
associated with an increased risk of carbamazepine-induced 
Stevens–Johnson syndrome. 
Sources: Policy Research Unit in Economic Evaluation of Health and Care Interventions[2]; 
American College of Clinical Pharmacy[7]; AAPS J[9]; J Neural Transm[10]; Aust New Zeal J 
Psychiatry[11]; J Clin Pharm Ther[12],[13],[14],[15],[16],[20]; US Food and Drug Administration[17]; Naunyn 
Schmiedebergs Arch Pharmacol[18]; Pharmacogenet Genomics[19],[21]; N Engl J Med[22]; Nat 
Genet[23]; Int J Immunogenet[24]; Epilepsia[25] 
There are guidelines to support the prescribing of more than 50 medicines where pharmacogenomic 
biomarkers are predicted to be of clinical relevance (see Table 2). 
Table 2: Medicines where actionable pharmacogenomic prescribing guidelines are available 
Therapeutic class List of medicines  
Cardiovascular system  
  
Acenocoumarol 
Atorvastatin 
Clopidogrel 
Fleicanide 
Metoprolol 
Propafenone 
Simvastatin 
Table 2: Medicines where actionable pharmacogenomic prescribing guidelines are available 
Therapeutic class List of medicines  
Warfarin 
Central nervous system 
Amitriptyline 
Aripiprazole 
Atomoxetine 
Carbamazepine 
Citalopram 
Clomipramine 
Codeine 
Desipramine 
Doxepin 
Escitalopram 
Fluvoxamine 
Haloperidol 
Imipramine 
Ondansetron 
Oxcarbazepine 
Nortriptyline 
Paroxetine 
Phenytoin 
Pimozide 
Sertraline 
Tramadol 
Trimipramine 
Tropisetron 
Venlafaxine 
Zuclopentixol 
Table 2: Medicines where actionable pharmacogenomic prescribing guidelines are available 
Therapeutic class List of medicines  
Gastrointestinal system 
Azathioprine 
Lansoprazole 
Omeprazole 
Pantoprazole 
Infections 
Abacavir 
Atazanavir 
Efavirenz 
Flucloxacillin 
Ivacaftor 
Peginterferon alfa-2a 
Peginterferon alfa-2b 
Ribavrin 
Voriconazole 
 Malignant disease and immunosuppression 
Capecitabine 
Cisplatin 
Daunorubicin 
Doxorubicin 
Flurorouracil 
Mercaptopurine 
Tacrolimus 
Tamoxifen 
Tegafur 
Thioguanine 
Rasburicase 
Other 
Allopurinol 
 
Table 2: Medicines where actionable pharmacogenomic prescribing guidelines are available 
Therapeutic class List of medicines  
Desflurane 
Enflurane 
Halothane 
Isoflurane 
Methoxyflurane 
Sevoflurane 
Succinylcholine 
Source: PharmGKB[26] 
Community pharmacy pharmacogenomic testing model 
Worldwide, the implementation of pharmacogenomic testing has largely been located in specialist 
academic centres[27]. These centres have adopted a pre-emptive panel approach to testing, which is 
where patients are tested for the presence of multiple pharmacogenes on admission[28]. The results 
are then entered into the patient’s electronic health record and integrated into clinical decision support 
systems. This way, prescribers are alerted to the patient’s pharmacogenomic result when prescribing 
a medicine that is impacted by the tested gene. 
Outside of these environments, examples are emerging of community pharmacy pharmacogenomic 
testing models[29],[30]. These models use commercial testing services (paid for by the customer) that 
provide laboratory testing, evidence-based interpretation, recommendations for clinical decision 
making and online platforms to store and report test results[31]. There is a range of services that 
employ pharmacists to deliver test results, available in the United States, Canada and Australia. 
Benefits of pharmacogenomic testing 
The aims of pharmacogenomic testing can be divided into two broad categories: 
1. Improving safety by reducing the incidence of adverse drug reactions; 
2. Improving the chance of therapeutic efficacy. 
Around 20 genes have been identified as having established clinical significance for more than 80 
medicines[32]. Randomised controlled trials support the use of pharmacogenomic testing to inform the 
prescribing of warfarin, abacivir and antidepressants[22],[33],[34]. 
There is evidence that suggests pharmacogenomic testing could have an effect on improving 
medicines adherence, improving confidence in deprescribing and facilitating shared decision 
making[35],[36],[37],[38]. These are all mechanisms that could support medicines optimisation[39].  
However, patients may not want to be involved with pharmacogenomic testing as they may not 
necessarily connect the benefits of testing to their health[40]. Patients have shown an interest, but 
willingness to pay for a service varies[40]. 
Training and end-to-end process 
Education and training are essential to the delivery of pharmacogenomic testing. Pharmacist training 
can come in the form of formal postgraduate programmes and online modules designed by the 
company performing the testing[41]. 
As part of the service set-up, pharmacists are encouraged to get in touch with local practices to 
educate them on pharmacogenomic testing. This is important as the pharmacogenomic test results 
need to be reviewed by a clinician if the results are to be actioned (see Box 1). Experience shows that 
doctors are receptive to pharmacogenomic advice offered by pharmacists[42]. However, it is important 
that these relationships are built early, especially if the report results are sent directly to the patient’s 
doctor. 
This model of testing carried out in Australia, Canada and America is not publicly funded and typically 
requires payment from the patient. 
Box 1: Example of steps involved in a commercial pharmacogenomic testing model 
1. The pharmacist identifies patients that may benefit from testing. These may be 
patients who have experienced therapeutic inefficacy or side effects with past 
medicines and have yet to find a medicine that works for them. 
2. The pharmacist explains what pharmacogenomic testing is and gives an 
overview of the testing process. 
3. The pharmacist takes consent for testing and a DNA sample (e.g. a cheek 
swab) from the patient. 
4. The pharmacist sends the swab to the laboratory along with the details of the 
patient and their doctor (who has been previously engaged with 
pharmacogenomic testing). The pharmacist makes a follow-up appointment 
with the patient to explain and deliver the test results. 
5. Test results are electronically sent to the doctor and the pharmacist to deliver 
to the patient. The patient does not gain access to their results prior to having 
them explained by their nominated healthcare practitioner (pharmacist or 
doctor). 
6. In the follow-up appointment, the pharmacist talks to the patient about how 
their pharmacogenomic results are likely to impact their current and potential 
future medicines, and discuss any non-genetic factors that may also influence 
drug response. If the pharmacist identifies any potential problems with the 
patient’s medicines, they will contact the patient’s doctor to discuss further. 
7. After the appointment, the patient is provided with access to their results 
through an online patient portal. The pharmacy at which the patient had their 
testing performed maintains a record of the results to help with alerting on 
significant gene–drug interactions for future medicines prescribed for the 
patient. 
How is testing carried out 
Commercial pharmacogenomic testing kits use different DNA collection methods. A popular method 
employed is a buccal (cheek) swab, owing to its simplicity and non-invasive nature[43]. A typical testing 
kit will be composed of a swab with a container to collect DNA and a pre-addressed envelope to send 
the sample to a laboratory. 
Example process for DNA collection: 
1. Open the pouch to remove the swab tube. The swab tube can be opened by 
pressing the upper part of the cap. The swab can then be removed by holding 
the cap and tube (it is important that the swab head is not touched with fingers 
because this would risk contamination); 
2. Insert the swab between cheek and lower gums of the patient and roll the swab 
ten times on the inner of both cheeks; 
3. The swab should be placed back into the tube firmly, until there is a click. 
Following these steps, there may be a need to fill out a form and return the swab to the testing facility. 
The facility will notify the pharmacist of the results after analysing the sample. 
Data protection 
In the UK, the EU General Data Protection Regulation (GDPR) governs data processing and 
protection[44]. The main implications for genetic testing in community pharmacy is to ensure consent 
for testing is ‘freely given, specific, informed and unambiguous’[45]. In addition, community pharmacies 
should ensure the company which is offering the pharmacogenomic testing service is GDPR 
compliant. 
How this could work in practice 
Although the process of pharmacogenomic testing is not currently carried out in community 
pharmacies in the UK, it may be part of future NHS services[3]. Therefore, it is important to understand 
how a development of this nature may impact future practice. The following example consultations are 
derived from experiences of that in Australia using paid-for pharmacogenomic testing kits through 
community pharmacy. 
Case study 1: genomic testing in an older person with depression 
Gary Jones, a retired teacher, has been referred to his pharmacy for a pharmacogenomic test by his 
GP. He is aged 62 years, recently widowed and is prescribed a standard starting dose of sertraline for 
depression[46]. The GP referred him to the pharmacy for a pharmacogenomic test because, after two 
months of treatment, he is still experiencing poor symptom control at night. 
Receiving consent and information giving 
You receive consent from the patient, collect a cheek swab sample and make an appointment for one 
weeks’ time, where you will review the test results with the patient. 
Results of the test 
The test results show the patient to carry the CYP2C19 *17/*17 genotype, which predicts the patient 
to have an ultra-rapid metaboliser phenotype for the CYP2C19 enzyme[44]. This makes him 
metabolise and clear sertraline very rapidly, reducing drug exposure and increasing the risk of 
therapeutic failure. 
Outcome of the test 
You explain to the patient that his gene results suggest that his body processes sertraline at a faster 
rate than other people, which may explain why the medicine’s effect wears off quickly compared to 
those who do not have the same gene variation. 
Options could be to increase the dosing frequency to twice a day, increase the daily dose, or change 
to another antidepressant that is not metabolised by CYP2C19. You contact the patient’s GP and 
forward them a copy of his report. The GP makes an appointment with the patient and decides to 
change the patient’s antidepressant from sertraline to venlafaxine. As the report suggests, the patient 
should have normal metabolism of venlafaxine via the CYP2D6 enzyme. The patient comes back to 
the pharmacy three months later and explains that he has responded well and that his depression is 
well managed by his new medication. 
The CYP2C19 genotype the patient carries also predicts a sub-therapeutic response to amitriptyline, 
citalopram, escitalopram, omeprazole and voriconazole at usual doses, with recommendations to 
increase the dose or choose alternative therapies in some cases, based on current pharmacogenomic 
guidelines[13],[14],[47],[48]. 
Case study 2: genomic testing for a patient taking warfarin 
Mary Thompson, aged 75 years, has been referred by her GP to her pharmacy for pharmacogenomic 
testing. She is due to have a tissue valve replacement in one month and her surgeon has explained 
that she will need three months of post-operative warfarin therapy[49]. Her GP wants her to have 
pharmacogenomic testing to help guide the initial dosing of warfarin. 
Receiving consent and information giving 
You talk her through the process of testing (see Box 1), take her consent and arrange a follow up 
appointment in a week’s time. 
Results of the test 
The report shows that she carries the CYP2C9*2/*3 genotype, which predicts her to have a CYP2C9 
poor metaboliser phenotype[16]. This results in significantly reduced metabolism of warfarin and 
increased anticoagulant effect. Her VKORC1 AA genotype predicts significantly reduced amount of 
VKORC1 (the enzyme warfarin inhibits), which is associated with an increased risk of warfarin 
sensitivity and lower daily dose requirements. Overall, reduced warfarin metabolism and increased 
warfarin sensitivity are predicted[16],[50]. 
Outcome of the test 
You explain to the patient that her genetic results predict her daily warfarin requirements to be 
between 0.5–2.0mg per day[51]. Many factors can influence warfarin dosing, such as diet, alcohol, 
weight and concurrent medications. However, when initiating warfarin, having knowledge of the 
genetic profile can optimise dosing[33]. You give a copy of the report to the patient to take to the 
hospital. You ensure that the GP also receives a copy of the report and ask them to inform the 
relevant anticoagulant clinic. 
After the operation, the consultant in the hospital started her on warfarin 1.0mg/day. The patient was 
able to get into the required international normalised ratio range of between 2.0 to 3.0 with no 
complications. In this instance, the availability of the pharmacogenomic result ensured the patient was 
prescribed a much lower starting daily dose and, therefore, encountered minimal adverse effects. 
The patient’s CYP2C9 genotype also predicts reduced phenytoin metabolism, leading to higher 
plasma concentrations and increased probability of toxicity[52]. 
Case study 3: genomic testing on pain relief 
Sheila Smith, a Caucasian woman aged 40 years, asks to speak to you as she is frustrated that her 
current medicines are not working — she is currently taking co-codamol to alleviate her “severe” 
lower-back pain. She is unable to take non-steroidal anti-inflammatory drugs as she gets a rash. 
Receiving consent and information giving 
You explain to her that her lack of pain relief from her current medicines may be influenced by her 
genes and a pharmacogenomic test can help determine if they appropriate. You talk her through the 
process of testing (see Box 1), take her consent and arrange a follow up appointment in a week’s 
time. 
Results of the test 
The report shows that the patient carries two non-functioning alleles for the CYP2D6 enzyme 
(CYP2D6*4/*4), which confers a poor metaboliser phenotype[53]. 
Outcome of the test 
You explain to the patient that codeine (as a prodrug) needs to be converted into morphine by the 
CYP2D6 enzyme, for which she has no function, and that she is unlikely to get sufficient pain relief 
from codeine-based analgesics. You reassure her that this is relatively common and that it occurs in 
about 5–10% of Caucasians[53]. 
You discuss the results with her GP and explain that tramadol and to a lesser extent oxycodone are 
unlikely to provide adequate pain relief as both drugs are metabolised to varying degrees by 
CYP2D6[53]. You suggest that potential alternatives that may be suitable for this patient are: regular 
use of paracetamol; low-dose morphine on an as-required basis; or a trial of buprenorphine if clinically 
applicable[13],[53]. 
Upon reviewing her results, the GP decided to switch her to regular paracetamol and a when required 
low dose of oral morphine. The doctor scheduled a review of her progress in a week’s time and, upon 
her return a week later, she reported much improved pain control with regular paracetamol and low-
dose morphine when required. 
The CYP2D6 genotype also predicts increased risk of side effects to tricyclic antidepressants, 
paroxetine, fluvoxamine, aripiprazole with recommendations to reduce doses or switch to alternative 
therapies[13],[14],[47]. 
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